Insmed (INSM) Q1 2020 Earnings Call Transcript

Insmed (INSM -3.12%)
Q1 2020 Earnings Call
Apr 30, 2020, 8:30 a.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Good day, and welcome to the Insmed first-quarter 2020 financial results conference call. All participants will be on listen-only mode. [Operator instructions] After today's presentation, there will be an opportunity to ask questions. Please note, this event is being recorded.

I would now like to turn the conference over to Sara Bonstein, chief financial officer. Please go ahead.

Sara Bonstein -- Chief Financial Officer

Thank you, Jason. Good morning, and welcome to today's conference call to discuss our first quarter's 2020 financial results and provide a business update. Before we start, let me remind you that today's call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements.

Please refer to our filings with the SEC, which are available through the SEC's website at www.sec.gov or from our website for information concerning the Risk Factors that could affect the company. We plan to reference a non-GAAP financial measure during today's call. For a reconciliation of GAAP measures to our GAAP results, please refer to the earnings release we issued earlier today. Additionally, the information on today's call is not intended for promotional purposes and not sufficient for prescribing decisions.

Joining me on today's call are members of the Insmed Executive management team, including Will Lewis, chairman and chief executive officer; Roger Adsett, chief operating officer; and Dr. Martina Flammer, chief medical officer. Let me now turn the call over to Will Lewis for prepared remarks. Upon completion of those remarks, we will open the call up for your questions.

Will?

Will Lewis -- Chairman and Chief Executive Officer

Thank you, Sarah. Good morning, everyone, and thank you for joining us. We hope you and your families are safe and healthy during these challenging times. The first quarter of 2020 will be remembered as one of the most trying in history in light of the unexpected personal and business disruptions brought on by this global pandemic.

For those of us at Insmed, the challenges posed by COVID-19 shine a bright light on the critical needs of patients living with serious and underserved diseases. We remain as committed as ever to our mission of serving these patients as well as the healthcare providers who care for them. We are pursuing this mission from a position of strength, and our solid balance sheet will enable us to stay the course with several meaningful inflection points along the way. I'll turn first to INS1007, which we are now calling by its new name, brensocatib.

Notably, last week, we announced the start of an investigator-initiated study of brensocatib in hospitalized patients with severe COVID-19. The results we observed from our Phase II WILLOW study in patients with non-cystic fibrosis bronchiectasis give us hope that the novel mechanism of action of brensocatib will have an impact on patients with acute respiratory distress syndrome, or ARDS, a devastating outcome of COVID-19 for which there are no currently approved therapies. We are proud to be a part of the innovative efforts in the fight against this pandemic. Martina will go into greater detail about this study and share new data from the WILLOW study on today's call.

We originally in-licensed brensocatib from AstraZeneca to explore its potential in patients with bronchiectasis. On the heels of the successful Phase II WILLOW study, we are continuing to advance brensocatib into Phase III development and expect to begin this program in the second half of this year. We believe that brensocatib also has the potential in multiple indications beyond bronchiectasis. We view this drug as a pipeline within our product and are increasingly excited about the future of what brensocatib may offer to patients.

Our belief in the potential of brensocatib was further validated last month when Astrazeneca exercised its first option under our license agreement, allowing AstraZeneca to pursue clinical development of brensocatib, up to and including, Phase IIb clinical trials for COPD or asthma. As a next step, we are working with AstraZeneca to form a joint steering committee for the development of brensocatib in either of these indications. Turning to ARIKAYCE. This quarter saw challenges, both expected and unexpected.

Nevertheless, we were able to produce solid revenue performance. Roger will address the impact of these cross currents during his remarks. Overall, we remain confident in the performance and potential of ARIKAYCE. As we look ahead, we are hopeful that we can accelerate growth in the second half of this year, assuming the COVID-19 situation continues to improve.

In the meantime, our team continues to adapt seamlessly to the current environment, finding new virtual ways to ensure patient access to and physician support for ARIKAYCE. We also look forward to initiating a front-line clinical study of ARIKAYCE and, in parallel, a study to validate the patient-reported outcome that will serve as the primary endpoint in the front-line study in the second half of 2020. Roger will go into more detail on these plans. Let me now turn the call over to Martina to drill down a bit more on the progress of our development programs.

Martina?

Martina Flammer -- Chief Medical Officer

Thanks, Will. And good morning, everyone. As Will mentioned, we believe brensocatib represents the opportunity to build the pipeline around the product. Let me remind you that brensocatib is a novel, oral, reversible inhibitor of dipeptidyl peptidase 1, or DPP1.

DPP1 is an enzyme that catalyzes the activation of neutrophil serine proteases or NSP, key agents of neutrophil-mediated inflammation. Last week, we announced the initiation of the superiority trial of protease inhibition in COVID-19 or STOP-COVID-19, an investigator-initiated study of brensocatib in hospitalized patients with COVID-19. The rationale for this study, which is being conducted by Professor James Chalmers at the University of Dundee, is that the patients with severe COVID-19, neutrophil influx into the line is a defined characteristic of acute respiratory distress syndrome, or ARDS. As Will mentioned, ARDS is a severe outcome of COVID-19 that is associated with high mortality.

It is believed that the reduction of neutrophil proteases in these patients may reduce the progression of lung injury and the need for mechanical ventilation. The STOP-COVID-19 trial is a multicenter, prospective randomized study, expected to enroll up to 300 patients with confirmed COVID-19 who present to the hospital at risk of needing increased levels of supplemental oxygen and/or ventilation. Patients will be randomized to receive either a 25-milligram dose of brensocatib once-daily or matching placebo on top of standard of care. The primary endpoint is clinical improvement on a seven-point ordinal scale as defined by the World Health Organization.

Patients will be treated for up to 28 days with the sample size reassessment performed once a hundred patients have been enrolled and treated. While the timing of the study is enrollment-dependent, we look forward to the sample size reassessment sometime in the third quarter of this year, with final data expected by the end of the year or early next year. Should brensocatib prove effective in this study, we believe the trial design could support a regulatory pathway for brensocatib as a potential treatment for patients with COVID-19 at risk for ARDS. In the meantime, we continue our efforts to advance brensocatib into Phase III development for bronchiectasis.

Bronchiectasis stands out as one of the more significant pulmonary diseases with no approved therapies. It is marked by frequent pulmonary exacerbations requiring antibiotic therapy and/or hospitalization. Prevalence estimates for non-CF bronchiectasis range from about 330,000 to 520,000 in the U.S., with significant overlap with patients who have nontuberculous mycobacteria lung disease, or NTM lung disease. Given the strength of the top-line results, we observed in the WILLOW study and subject to our discussions with the FDA, we plan to focus the Phase III program on bronchiectasis patients with two or more exacerbations within the prior year.

We expect to initiate this program in the second half of 2020, following alignment with the FDA on the trial design. We're also planning to share additional results from the Phase II WILLOW study during a virtual forum anticipated to be held by the American Thoracic Society, or ATS. While we will provide a more detailed update at that time, we can share that our analysis of the data validates top line results. For example, we saw a significant improvement for several of the QOL-B domain, including physical functioning, emotional functioning, vitality, and health perception.

In addition, changes in FEV-1 showed a trend in favor of brensocatib over placebo, even in the six-month study. Finally, in addition to the reduction of sputum neutrophil elastase that we observed with the -- with brensocatib as a result of its mechanism of action, we have also observed a correlation between sputum neutrophil elastase reduction and the reduction of pulmonary exacerbations based on pharmacokinetic and pharmacodynamic modeling analysis. The overall safety profile was similar across treatment groups. However, headaches, skin, and dental-related adverse events were numerically higher with brensocatib than with placebo.

Following the virtual ATS forum, we plan to host an investor call with a key opinion leader featuring the data. We look forward to sharing further details and the broader set with you once the details of this virtual ATS sessions are finalized, which we currently expect will be before the end of June. Beyond bronchiectasis, we believe that brensocatib has the potential to be effective in treating other neutrophil-driven diseases, including cystic fibrosis. CF patients have even greater levels of neutrophil elastase than bronchiectasis patients.

And therefore, we believe brensocatib may benefit CF patients by addressing the harmful effects of neutrophil elastase in inflammation and sputum production. While our corporate development interest for this compound remains with bronchiectasis and CF, there is a biological rationale that the brensocatib may be applicable across a broad range of indications, including alpha-1 antitrypsin deficiency, granulomatosis with polyangiitis, inflammatory bowel disease, lupus, and rheumatoid arthritis. And as Will mentioned earlier, AstraZeneca has exercised its option, which allows for the pursuit of clinical development of brensocatib in COPD or asthma subject to our ultimate agreement regarding commercially acceptable terms. Our pipeline also includes INS1009, which we are now calling by its new name, treprostinil palmitil.

This is a dry powder inhaled treprostinil prodrug formulation that we are advancing for the potential treatment of pulmonary arterial hypertension or PAH. We remain on track to file an IND and initiate a Phase I study of treprostinil palmitil later this year. We're very excited about the multiple opportunities in our pipeline. Let me now turn the call over to Roger to discuss some key operational updates, including the ARIKAYCE franchise.

Roger?

Roger Adsett -- Chief Operating Officer

Thanks, Martina. And good morning, everyone. I'm pleased to report that from an operational perspective, we continue to execute on our strategy, delivering across all areas of our organization, including research and development, manufacturing, and international expansion. While we have adjusted our approach significantly, we continue to support our customers and patients and execute at a high level across medical affairs and commercial.

As we previously shared, COVID-19 has had an impact on our U.S. commercial efforts related to ARIKAYCE. In mid-March, we pulled our sales force from the field to ensure the safety of our team, our patients, and physicians, and to respect the tremendous efforts that healthcare professionals were directing to the care of COVID-19 patients. Our first-quarter sales were also impacted by the expected reset of deductibles, including the donut hole effect.

Notwithstanding these obstacles, we announced early today total net sales of $36.9 million for ARIKAYCE for the first quarter of 2020. I'm extremely proud of the commercial team's ability to deliver this result in the face of significant challenges we faced. To dig a bit deeper, we are seeing regional variability around the response to COVID-19 and the impact it is having on ARIKAYCE, but no clear trends have emerged. In light of the necessary adaptation of our sales force to a remote model, we expect new patient adds to be modest in the near term.

That said, while these are challenging times, we remain confident in the long-term strength of the ARIKAYCE franchise and are hopeful that we can continue to grow in the second half of this year, assuming the COVID-19 situation continues to improve. In the meantime, our teams are continuing to support customers through virtual engagements, and we are encouraged that physicians are continuing to start new patients. Additionally, in recent survey work with targeted physicians, over half of the targets say they anticipate an increase in their index of suspicion for pulmonary infections, with the majority of those saying they will test more often. In fact, 2/3 of those surveyed say they will bring patients into the office with urgency to assess their progress and consider changes with current treatment when the crisis subsides.

We were also encouraged to see that existing patients are remaining on therapy, and new patients are receiving support. Our ARIKAYCE trainers are providing remote training for new patients, and our ARIKAYCE coordinators provide frequent remote support for existing patients and doctors. Patients have expressed how much they appreciate the support Insmed continues to provide, and that the comfort and familiarity of hearing from the coordinator is especially meaningful right now. In addition, our market access team is working with payers to address patient and physician access to diagnostic tests.

We are pleased that most payers are extending reauthorization times and/or waiving certain reauthorization requirements. It's extremely encouraging that payers have acted quickly to ensure NTM patients continue to have access to their medication throughout this crisis. I'm also pleased to note that, to date, our supply chain and manufacturing infrastructure remain intact. To date, patients on drug continue to receive drug shipments with no interruptions.

We believe we have an adequate supply of the active pharmaceutical ingredient used in ARIKAYCE to meet our anticipated global requirements, including commercial, clinical, and compassionate use through the end of 2022. ARIKAYCE may also benefit from two other potential catalysts for growth. First, a peer review paper was published in early March that provides potential practical solutions to address the most common adverse events that can accompany the use of ARIKAYCE in the treatment of refractory lung disease caused by Mycobacterium avium complex or MAC. We expect that these practical solutions will serve to improve patients' continuation on therapy.

And second, we continue to anticipate the introduction of a set of new treatment guidelines for multiple scientific societies, including the American Thoracic Society, the Infectious disease Society of America, and the European Respiratory Society, which we will remain optimistic will support the use of ARIKAYCE for appropriate patients. While we await the new guidelines, we are encouraged that on our recent European Respiratory Society webinar, a member of the committee announced that ARIKAYCE will be included in the guidelines, with a recommendation that it be added to background therapy if a patient remains culture positive after six months of treatment. This is consistent with our clinical trials and U.S.-approved labeling. We are excited about the potential inclusion of ARIKAYCE in the guidelines and the impact it may have, especially with community pulmonologists and infectious disease specialists.

We view the anticipated arrival of these guidelines as an important opportunity to reinforce the appropriate approach to treating refractory MAC patients, including the recommended duration of therapy for these patients. Let me turn now to our global expansion efforts in both Japan and Europe. In Japan, we have submitted a new drug application to the Ministry of Health, Labor and Welfare for ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment. As we previously disclosed, we plan to deploy an Insmed sales force dedicated to educating Japanese physicians on MAC lung disease and promoting the appropriate standard of care regimen, including the use of a macrolide to treat patients.

We expect to begin to hire our sales team when the global health crisis will allow us to safely execute on this opportunity. Once the pandemic subsides, we intend to allow our sales force, in compliance with Japanese law, to establish and build relationships with physicians who are treating MAC lung disease patients. In Europe, as previously shared, our marketing authorization application has been validated by the European Medicines Agency. And we expect that if it is approved, we could potentially launch ARIKAYCE by the end of the year in Germany, with the U.K.

following shortly thereafter. Finally, let me turn to our efforts around label expansion for ARIKAYCE. We are advancing ARIKAYCE in a front-line study that, if approved by the FDA, would allow us to address the estimated 95,000 to 115,000 patients in the U.S. diagnosed with NTM MAC lung disease and that will serve as the necessary confirmatory study for ARIKAYCE, as agreed in that post-approval commitment with the FDA.

We anticipate that this study will also address front-line approval requirements for Europe and Japan, using the primary endpoint of durable culture conversion, which we intend to discuss with the relevant regulatory authorities. We plan for a study duration of 13 months, with treatment for 12 months, followed by one month off therapy. The primary endpoint of this study in the U.S. will be a composite patient-reported outcome, or PRO, in order to demonstrate the clinical benefit, which is required by the FDA.

We expect that the validation of the PRO and the confirmatory study will track in parallel, pending alignment with the FDA. We remain on track to initiate these trials in the second half of 2020. In these challenging times, we are working diligently to maintain the strength of the brand and maximize the long-term potential of ARIKAYCE in the U.S., Europe, and Japan. I'm very excited about what lies ahead, and I want to thank the team for their continued commitment to the NTM community.

From a strategic perspective, when we look at our product portfolio through a broad lens, we see an impressive potential commercial overlap among our programs, particularly the synergies between NTM and bronchiectasis. And we're excited about advancing treprostinil palmitil, a promising medicinal candidate for a rare pulmonary disease. We remain committed to advancing these programs and look forward to sharing our progress with you. I'll now turn the call to Sarah, our chief financial officer, for the financial update.

Sarah?

Sara Bonstein -- Chief Financial Officer

Thanks, Roger, and [Inaudible]. In the first quarter of 2020, we made significant progress across all of our programs, maintaining a keen focus on the management of our operating expense. As Will mentioned at the start of the call, Insmed is well-positioned to support the next wave of its growth through multiple value inflection points. In the current climate, operating expenses are as difficult to predict as revenue.

For the first quarter, our operating expenses were well below budget. While we continue to face uncertainties brought on by COVID-19, we can say that our cash runway, coupled with our focus on appropriate spend, leaves us confident that our financial resources could carry us into 2022. Our quarterly results are detailed in our press release issued this morning. For today's call, I want to draw your attention to a few key line items.

This morning, we reported total net revenue for the first quarter of $36.9 million, comprising $35.2 million in U.S. net sales of ARIKAYCE, and $1.7 million in ex-U.S. net sales of ARIKAYCE. The ex-U.S.

net sales reflect utilization from the compassionate use and named patient programs in both France and Germany. Total net revenue increased 68% as compared to the first quarter of 2019. Our gross to net for the first quarter were approximately 14%, similar to what we saw in the first quarter of 2019. While we anticipated our gross to net in Q1 to be higher due primarily to the coverage gap as a result of the benefit reset at the beginning of the year, we reiterate our previous guidance of our gross-to-net for the full year to be in the mid-teens.

Cost of product revenues for the quarter was $8.4 million, and gross margin was approximately 77%. As a reminder, our gross margin in 2019, which was 81%, benefited from inventory expense prior to FDA approval of ARIKAYCE. And we do not anticipate this will continue at a similar rate in 2020. Turning to expenses.

For the first quarter of 2020, research and development expenses were $36.2 million, and SG&A expenses were $51.3 million. Our GAAP operating expenses for the first quarter were $88.8 million compared to $87.3 million for Q1 2019. We define adjusted operating expense in our earnings press release as GAAP operating expenses, excluding stock-based compensation expense, depreciation, amortization of intangibles, and certain milestones related to ARIKAYCE payable under our amended agreement with Cystic Fibrosis Foundation Therapeutics. In first quarter of 2020, our adjusted operating expense was $76.3 million compared to $78 million in the first quarter of 2019, highlighting our continued efforts and focus on cash discipline and preservation.

For 2020, we will continue to invest in our core operating business, which includes continued commercialization of ARIKAYCE, global expansion activities in both Europe and Japan, and pipeline advancements. In addition, we will invest in the planned Phase III program for brensocatib. We ended the quarter with a strong cash position of $428.9 million. We intend to maintain a strong balance sheet where we manage appropriate development investment with responsible cash management.

With that, let me turn the call back to Will for closing remarks. Will?

Will Lewis -- Chairman and Chief Executive Officer

Thank you, Sarah. Let me close out our prepared remarks by reiterating that we are extremely proud of the continued execution by the team at Insmed. We believe we are advancing a pipeline of high-value opportunities in areas of stark, unmet medical need. In tandem, we believe our commercial efforts for ARIKAYCE have enabled us to create a strong franchise with great future potential globally and across additional indications.

I want to congratulate the Insmed team for staying the course and making tremendous progress in these uncertain times. We all remain very excited about what lies ahead for the company. With that, I'd like to open the call to questions. Operator, can we take the first question, please?

Questions & Answers:

Operator

Yes. We will now begin the question-and-answer session. [Operator instructions] The first question comes from Matthew Harrison from Morgan Stanley. Please go ahead.

Matthew Harrison -- Morgan Stanley -- Analyst

Hi, all. Thanks for taking the question. This is Connor Meehan, on for Matthew. So just a couple from us.

How has the physician and patient engagement trends during COVID -- I know you guys mentioned the digital sales force, and I guess, we were just looking for maybe some more color on that. And then could you provide some guidance on how new diagnosis for NTM have fallen off, if they have? Thanks.

Will Lewis -- Chairman and Chief Executive Officer

Appreciate the question. I'm actually going to turn this one over to Roger to sort of address from the commercial point of view.

Roger Adsett -- Chief Operating Officer

Thanks, Will. Yes, so I think that we've had tremendous engagement from physicians and healthcare professionals, the office staff in a very trying circumstance. So, we have the digital engagement from our sales team. We have the virtual training from our ARIKAYCE trainers.

We have engagement from our ARIKAYCE coordinators. Now I would say there's regional variation, with some areas of the country have been hit a lot harder than other areas, and that's made, obviously, the priority of physicians to focus on COVID-19 rather than an NTM patients. But I would say that the biggest challenge we're seeing right now is just the patients -- we did some survey work that I mentioned in the prepared remarks. We did some survey work and I think what physicians are telling us is the biggest challenges they're seeing is just the number of patients who aren't comfortable coming into the office yet.

We're certainly seeing a rise in telemedicine, but that hasn't offset the volume of patient visits that you would expect in a normal situation. Having said that, we also mentioned that the physicians have moved to managing patients and making sure that they stick with their therapy and continue on their therapy for the patients who are already on ARIKAYCE. So, they really turned their attention away from the new patients because the opportunity is not there right now as robustly as it was previously, but the -- they're focused on making sure that the patients already on therapy continue. And as we mentioned, there's an increase in index of suspicion that they reported, with over half of the physicians reporting an increase in that index of suspicion with an intention to do more screening once these patients return.

And also, over -- about 2/3 of these physicians report with pulling the NTM patients in with some urgency, so proactively asking them to come in for screening and to manage their NTM rather than waiting for them to make appointments. So, I think all of those trends are very encouraging. I think that what we'll see is this is just a delay. We're pushing out these diagnoses.

And certainly, we could expect if the -- based on those survey results, we may see, in the second half of the year, we may see a bolus of these NTM patients coming in for therapy.

Will Lewis -- Chairman and Chief Executive Officer

And I would just add to that. I think one of the interesting and unintended features, of course, of the global pandemic is, this increased attention to respiratory condition generally. So I think we will be the beneficiary of that as it goes forward. Now is actually the time to be a company with products that are focused and developmental product candidates that are focused on pulmonary health.

Matthew Harrison -- Morgan Stanley -- Analyst

Great. Thank you.

Operator

The next question comes from Adam Walsh from Stifel. Please go ahead.

Adam Walsh -- Stifel Financial Corp. -- Analyst

Hey, good morning. Thanks for taking my questions. My first one is you mentioned the donut hole in the first quarter of 2020. Do you feel that, that's behind you now in terms of [Inaudible] the impact on the ARIKAYCE in the first quarter?

Will Lewis -- Chairman and Chief Executive Officer

Yes. The short answer to that is yes. I think it was behind us much earlier in the year. And in fact, we pretty much put it in the rearview mirror, and then we got hit with COVID.

So, it was an interesting first quarter, as you've seen. The good news is, I think the team responded very well to that. And then I would just say, structurally, you know, the donut hole is something that you're going to encounter every year. I think we moved through it pretty quickly.

It doesn't speak to fundamental demand or interest in writing a prescription. It speaks to the delay of the initiation of therapy. I don't know, Roger, if you'd add anything to that?

Roger Adsett -- Chief Operating Officer

And I would agree with that, Will. I think we're well past that, and we're working our way through that. And as you mentioned, this is -- this just slows down the processing while the patient lines up assistance to meet those co-pays. And we think we're on the other side of that now.

Adam Walsh -- Stifel Financial Corp. -- Analyst

That's helpful. And then a couple of quick ones here. For Sarah, you mentioned supporting the STOP-COVID-19 trial. What does that mean in terms of increased cost outlay or spend? And then one final one on 1007.

You mentioned kind of numerical trends for periodontal disease with that. I'm just curious. Kind of what are the thresholds of periodontal disease that might cause concern? Thank you.

Will Lewis -- Chairman and Chief Executive Officer

Yeah. So, I'll let Sarah answer the first one on the costs related to COVID-19.

Sara Bonstein -- Chief Financial Officer

Yeah. Thanks, Adam. I appreciate the question. Immaterial, for providing drug and some nominal cost that's immaterial from a total cash operating expense input.

Will Lewis -- Chairman and Chief Executive Officer

Yeah. And then on the issue of periodontal disease, I just want to be clear. The reason we looked at this is because if you look at patients who have Papillon-Lefevre syndrome, which is a total absence of DPP1, they tend to have increased levels of periodontal disease. So, we included periodontal disease as a rate -- as one of the adverse events of special interest.

And we tracked it very closely. That meant that we had a dentist literally inspecting each patient throughout the course of the study. And as you may recall from the top-line data we released, if you look at the different percentage rates of so-called periodontal diseas,e in placebo, it's 2.4%; at the 10-milligram arm, it was 7.4%; and in the 25-milligram arm, it was 10.1%. None of this led to discontinuation of the drug, but it was something we were tracking.

And the characterization of periodontal disease was a minimal change in the recision level of the gum, if I remember it correctly, and the consequence of that was not considered to be meaningful. I don't know, Martina, if you want to add any characterization to that particular item, and how we're going to think about that going forward.

Martina Flammer -- Chief Medical Officer

Yes, Will. That's correct. So we measure truly if there is a change in the gum pocket and have that also independently assessed. And based on what we've seen in Phase II, we don't, right now, anticipate that we will have this type of dental monitoring in Phase III.

We will discuss this with the agency. But that is what's the current testament based on the data.

Will Lewis -- Chairman and Chief Executive Officer

And I think the final point of encouragement there is that our DPP1 inhibitor, in contrast to others that were developed, is reversible, and we demonstrated this very clearly in the Phase II study. So that even if we were to get to a place where somehow this was viewed as something to be watched carefully, it's something we can always accommodate by discontinuing the drug and seeing the reversibility and the return of DPP1.

Adam Walsh -- Stifel Financial Corp. -- Analyst

Thanks.

Operator

The next question comes from Marty Auster from Credit Suisse. Please go ahead.

Martin Auster -- Credit Suisse -- Analyst

Hey, all. Thanks for taking the question. I had a couple of pipeline questions this morning. I guess, first, Roger, you're talking about the PRO study and the validation of the PRO kind of being conducted in parallel with the confirmatory study.

I was curious if that validation is likely to then be released to us ahead of the confirmatory readout. And obviously, the timelines are a little bit in flux right now. But assuming you start that trial later this year, with that validation readout, how far in advance of the final data would that occur? And would that allow you to kind of, I guess, resize the trial or modify the PRO? And the second question I had was on treprostinil palmitil. I'm curious what you guys are thinking about in terms of defining success of the Phase I trial.

Are you looking to show kind of comparability to the currently [Inaudible] Treprostinil and [Inaudible] how you could find that through plasma PK measures? Or are there other measures you're thinking about? And then what if successful Phase I allow you to advance right to registrational study in PAH, as well as any other approved indications for today's [Inaudible]? Thanks.

Will Lewis -- Chairman and Chief Executive Officer

So, appreciate the questions, Marty. The first I would say, on the frontline study, there are two components to that: one is this -- the actual study that will secure approval for the indication of front-line use ARIKAYCE in MAC patients. That study will run for 13 months in length. It will use the PRO as the primary endpoint.

In parallel, we'll be running what I call, the sentinel study, which is effectively a way to address the uncertainties that surround the use of a previously unused PRO, which we've seen in other areas of biotech development. So, this was a response to that. And the way we do this is by validating the PRO in a parallel study. That study, the validation study, will run for seven months.

So, the consequence of that is, we will know the information on the PRO validation study, you know, if these are running at the same enrollment rates, et cetera, a half year before we would have the results of the main study. And yes, indeed, the intent is that if we learn things from that study, we can utilize them to adjust the main study which will still be blinded. So that's a really important point about that sentinel study. Validates the PRO, we'll see how it responds in this population and, as and when necessary, we can either adjust enrollment or even indeed, the composition of how we think about the PRO prior to the unblinding of the main study.

So that study will release that information. The sentinel study earlier than the main study, and that should give investors and the market, generally, an understanding of how that PRO is responding. So, we're super excited about that. We remain in a good place with regard to the FDA and their acceptance of this approach.

And I think that's a statement about their interest in seeing this developed in a way that can bring about a successful approval, assuming that the study demonstrates that. In the case of 1009, we'll be entering Phase I this year. What has got us so excited about this. And I'm often asked, you know,when we were looking at 1007, people said, you know, how do you feel about that program? And I said well, it's kind of a lottery ticket.

And then the lottery ticket won, and it won huge. When we look at the rest of the company, people often say, well, do you have any other of those lottery tickets? I think 1009 represents another lottery ticket. And the reason we say that is because if you look at the animal data, where we actually have compared treprostinil palmitil to other compounds, we are continuing that work. And to revalidate it, we saw a dramatic difference in terms of what our drug could accomplish in the animal model setting, including disease modification.

And that got us very excited about its potential. So, Phase I is an ascending dose study. We will be moving as quickly as possible on the heels of that into what we will call, sort of, a validation study in patients who have PAH. The goal here is to get as quickly as possible into disease patients to see if we're seeing the same kind of modification outcomes that we have seen in the animal setting.

If indeed that's the case, we know from our target product profile research work, which we've done over the years. And while it's early, nonetheless, we've heard some very encouraging response from physicians that they would alter the way they utilize treprostinil as a drug if our data were to carry through and show in humans what it's shown in animals. So that's where we are. We expect that, that study would begin next year, assuming that Phase I goes through successfully this year.

Generally, I would say the path to get from here to there is not that long in time and will not be that expensive. So, we will have an answer to whether we have what we would consider a significant addition to the treatment of PAH in 2021.

Martin Auster -- Credit Suisse -- Analyst

Thanks, Will.

Will Lewis -- Chairman and Chief Executive Officer

You bet.

Operator

The next question comes from Ritu Baral from Cowen. Please go ahead.

Ritu Baral -- Cowen and Company -- Analyst

Good morning, guys. Thanks for taking the question. Can you talk a little bit about what you're seeing in Q2 as far as ARIKAYCE? How much comfort do you have on the visibility into this current ongoing quarter based on Q1? You know, are those geographic impact that you're seeing continuing? And as you think about those new patients start, given how, I guess, the clinical trial sites and clinical sites, in general, are thinking about reopening or thinking about changing how they see patients, do you see new patients start changing in, or an inflection in second quarter? Or is it necessarily the second half?

Will Lewis -- Chairman and Chief Executive Officer

Yeah. So, it's a great question, and it's sort of at the heart of what we think about every day. I'll turn it over to Roger in a second to add his perspective, but I would just characterize COVID-19 as creating a great deal of uncertainty in the marketplace, as we're all aware. And I think, geographically, variability is the watchword for what we've experienced.

I will say, though, notwithstanding all of that, and I have to call this out, the commercial team, as a whole, have done an exceptional job of making it possible for patients to initiate drug, to continue drug, and to, you know, receive the benefit of this therapy. We have seen new patient starts in the most challenged locations like New York City. So, I think that is a remarkable outcome in amid of what is obviously a very distracting circumstance. Roger, I'd -- you're much closer to this than I am.

What might you add to that?

Roger Adsett -- Chief Operating Officer

Yeah. Thanks, Will. I would only add that, as we mentioned, I think the most challenging aspect that physicians are talking -- telling us is just that patients are postponing or canceling their visits. And there's some -- and so it's -- as states reopen and as they make the decision on how they're going to reenter into some semblance of normalcy, that -- those patient visits coming back is going to be a major driver.

And as we mentioned, physicians are looking to call those patients in proactively. So while I can't pinpoint exactly when that's going to happen, and it will vary from state to state, depending on the impact of COVID and depending on how Governors make the decisions to reopen businesses, and as patients become comfortable, engaging with their physicians in an in-person perspective, then we'll see -- I believe we will see that -- the rebound in adding new patients. But as Will said, we continue to add new patients, and I think that's very encouraging. We think that there will be a bolus, and as we describe it, in the second half of the year as these patients become more comfortable in going back into the physician's offices.

In the meantime, I would also like to add my thanks to the commercial team for all the work that they've been doing. We've pivoted toward the digital interaction with physicians. We're working on materials so that physicians can have constructive and productive conversations with their patients over telemedicine as we see the adoption of telemedicine. The physicians are reporting that they've really adopted that in earnest, and patients are taking advantage of that.

And so, the materials that we provide to the offices and to physicians to have constructive educational conversations with their patients. We are also repurposing so that they can use those in a virtual setting as well. So, I think we're doing everything we can. So as soon as we get that back to some semblance of normalcy, we'll be seeing the acceleration and additional growth.

And like I've said, I think the opportunity remains intact. It is a very strong set of dynamic that's building in my mind. And as Will said, I think the impact and the focus on respiratory health, you know, the damage that occurs to the lungs from -- even from patients who recover from COVID or an asymptomatic, I think, is also going to play out over time, and we'll see how that plays out. But certainly, physicians have reported to us that they're paying much more attention on their index of suspicion going up for NTM.

And I think we're going to be there to help support physicians as they go through that journey with the patients.

Ritu Baral -- Cowen and Company -- Analyst

Roger, just to clarify something that you said. You mentioned the states reopening. Based on your conversations with doctors, how much are they actually paying attention to that given some of the aggressiveness of the timelines? Are they telling you that, yes, it seems that their patients will pay attention to that and start coming in? Or are we necessarily thinking about some sort of lag upon reopening before those patients feel comfortable coming in?

Will Lewis -- Chairman and Chief Executive Officer

Go ahead, Roger.

Roger Adsett -- Chief Operating Officer

Yeah. Thanks, Ritu. So, what they're telling us is that the patients are canceling their appointments or postponing their appointments. So, I think it's going to be -- as we talk to the patient advocacy groups, it's certainly top of mind as we've got a patient population that is potentially more vulnerable to COVID-19.

So that's where I think it's going to be a combination of telemedicine as well as the in-person visit. But certainly, for new diagnoses, it's easier to do this over -- in-person, but we have reports of physicians who are able to make the diagnosis and are able to initiate new patients on ARIKAYCE using telemedicine. They figured out how to do this. So, I think it's going to be a combination of both.

And ultimately, it's going to be when patients decide that they're ready to go back into the offices is going to be the controlling factor. Physicians are anxious, particularly in areas where they're not overwhelmed with COVID-19, and they're not being called in a hospital. Physicians are anxious to reopen and get their practices back on track. And certainly, they're concerned -- the targets that we've talked to, they're concerned about the health of their NTM patients.

Ritu Baral -- Cowen and Company -- Analyst

Got it. And just a quick follow-up question, more housekeeping than anything. In your 1007 Phase III study, what's left to discuss with FDA? I mean it sounds like you've hashed out the primary endpoints in all of the geographies. Do you have the final design in hand? Or is there an FDA meeting left to have before you can start the Phase III?

Will Lewis -- Chairman and Chief Executive Officer

Yeah. So, we're not going through the sort of back and forth with FDA not -- for any reason other than just that the -- there is nothing really there in detail to share at this time. I think what we really want to do, and what I've always -- the practice, I've always followed is wait until we have the definitive answer from FDA where everything is resolved, and then we can come out and share with everyone the details. But the discussion of the Phase III study, our approach with this compound, I think we are sitting on a mountain of very encouraging data, and we want to make sure that the Phase III, as a principle of design, varies little from Phase II because we're studying the relevant endpoints in Phase II and just simply carrying that over to Phase III.

If you think about the history of drug development in bronchiectasis, the challenge has been that every company prior to us, to the best of my knowledge, has always had to change the primary endpoints they're focusing on in Phase III from their Phase II program, and their Phase II programs have always been very small. In our case, we had more than 250 patients studying the relevant primary endpoint that would be needed for approval in Phase III. So, all we have to do is replicate Phase II to secure access and approval from FDA. And if we accomplish that, we'll be the first ever approved drug to treat a disease that has hundreds of thousands of patients in the U.S.

And we'll be treating it with a chronic approach with a once-a-day pill that had a dropout rate that was higher in placebo than in the treatment arms. I mean, I went over the periodontal disease, but I just want to remind everybody the rates of adverse events leading to discontinuation were 10.6% in placebo versus 7.4% in the 10-milligram arm and 6.7% in the 25-milligram arm. So, we are sitting with a very attractive safety profile and great clinical data that we think is going to pave the way for approval. And we'll get those final details nailed.

And once they are, we'll share it with everyone.

Ritu Baral -- Cowen and Company -- Analyst

Got it. Thanks for the detail.

Will Lewis -- Chairman and Chief Executive Officer

You bet.

Operator

The next question comes from Joe Schwartz from SVB Leerink. Please go ahead.

Joe Schwartz -- SVB Leerink -- Analyst

Great. Thanks so much. I was wondering if you could give us any sense of the order of magnitude reduction in new patient add since the pandemic hit. It would be helpful for us to calibrate our models, if you could give us any insight into what you're seeing in terms of, for example, how many patients have started ARIKAYCE in the post-COVID world versus the pre-COVID world?

Will Lewis -- Chairman and Chief Executive Officer

Yeah. I appreciate that question, Joe. I think as Roger said in his prepared remarks, and I'll turn it over to him in a second, it's really hard to discern any trends that we think are reliable enough to be able to use as predictors. And we don't really want to go into splitting it down to that level of detail.

But Roger, I don't know, do you have any color you can add with regard to this question?

Roger Adsett -- Chief Operating Officer

Yeah, thanks, Will. So, I think what I would add to that is just the number of patients and the physicians who are recording the reduction in visit. So, about 2/3 of the -- of our healthcare professionals say that they've been impacted by this with fewer NTM diagnoses. So, it's about 1/3 report, they're about the same.

And 2/3 say there are fewer NTM diagnosis. And the primary reason for that is the patient's postponing or they're canceling the visits. And so, as I said, I think that the return to accelerating our growth here is going to be dependent on the patients getting back into the offices and physicians continuing to adapt to telemedicine.

Will Lewis -- Chairman and Chief Executive Officer

And it's difficult, Joe, to give you more detail there because I think the other thing that's operating is that while we are beginning to see certain things in certain regions, that variability gets compounded by the fact that some physicians, through their practice and their experience now, are finding new ways to address their interactions, right? So, think about the first early news came out about COVID-19 and everybody was in a reactionary mode and they were focused exclusively on preparing the hospitals and shutting everything down. And now I think enough time has gone by. The people are going to find their way back to the new normal. And there will be variability across the region as to how that happens.

But you know, physicians know that patients with serious pulmonary conditions can't be postponed forever. I mean, one of the most remarkable statistics in the context of COVID-19, in my opinion, has been the drop in hospitalization rate for people with heart attack and stroke. Those things don't go away, and they are not optional for treatment. Nonetheless, the rate of treatment for those kinds of conditions has gone down.

We would expect the same kind of response here in the sense that you can postpone for a little while, but not forever. And I think physicians are very focused. And we've heard their gratitude expressed to us for our helping them in new and appropriate ways to be mindful about how to look out for their patients who have this disease. Remember, this is where – this is a group of patients who are refractory.

They've been treated for a very long time unsuccessfully. They now need to be treated with something additional in the judgment of the physician. And so, whatever we can do to help them, they are trying to find a way to make that happen.

Joe Schwartz -- SVB Leerink -- Analyst

OK. That's helpful. And then how do -- how well do you think your commercial team is prepared to deal with a bolus in the second half if we get that? And, you know, as we get a taste of some semblance of normalcy, at least in some regions of this country going forward, at least for a brief spell, how do you expect to manage your sales and marketing efforts? And how does the geographic variability of the disruption you've seen so far? And what you expect to see when things open up, set up, or correspond with how your sales force is set up geographically? And do you see any need to make any adjustments in any of it?

Will Lewis -- Chairman and Chief Executive Officer

Yeah. So, the first thing I want to say before I turn it over to Roger to talk about, you know, what the sales force is doing right now is, I would put the sales force against any on the street, period. They have delivered time and time again. And I think what is remarkable about them, from my interaction with them, is they remain deeply committed to helping these patients.

And I would say, they're not at all shaken by the fact that they've had to step out of their normal routine. They are finding new ways to get ready to address this bolus. So, when it comes, if it does as we expect, they will be ready. And Roger, you want to talk a little bit in more detail about what they've been doing and how you think about this?

Roger Adsett -- Chief Operating Officer

Yeah, thanks, Will. I would agree with that. I think what's been remarkable in my mind and as I watch the sales team and the ARIKAYCE coordinators and the trainers is just the adaptability and the willingness to engage and support physicians and patients and healthcare professionals through different means, right? And so, it's been a real pleasure to watch. And I have no qualms at all if -- when we see this increase in patients.

And if we do get to this bolus that the survey is predicting based on the physicians or the targets we talked to, I think we are well-positioned to handle that. We have our intact sales team, we have our PAL team, patient access leaders, who support the reimbursement process. I think, as I mentioned on the -- in the prepared remarks, payers have been remarkably supportive here, and that's very encouraging. And we expect to be able to continue to process and have access to -- for patients to have access to ARIKAYCE with minimal disruption based on attestation for physicians who prescribe.

We're prepared to talk and support the patients virtually. So, we've had a very strong response to virtual interactions and training with our ARIKAYCE field trainers in onboarding patients, training them on how to use the device and what to expect from therapy. And that's something that we can continue to offer. So, I think what's happened here is, the way that the marketing team and the sales team have pivoted to the new situation has actually added new arrows to our quiver.

And so. we've got new tools, and we've got new ways to successfully support patients and healthcare professionals, and I think that's going to serve us really well as we get on the other side of this and get to some sense of normalcy in the second half of the year.

Joe Schwartz -- SVB Leerink -- Analyst

Thanks for all the color. Best wishes.

Will Lewis -- Chairman and Chief Executive Officer

Thanks, Joe.

Operator

The next question comes from Liisa Bayko from JMP. Please go ahead.

Liisa Bayko -- JMP Securities -- Analyst

Hi. Thanks for taking my question. Do you have any sense on the sort of size of this group of warehouse patients? Is there any quantitation you can give us or [indiscernible]

Will Lewis -- Chairman and Chief Executive Officer

I don't know that there is at this point. I think the way I would describe it is there are a number of vectors that are coming together here, and they're going to contribute to that, right? And I think they are both the immediate byproduct of delay and treatment of COVID-19 -- caused by COVID-19, plus potentially the arrival, as we talked about even prior to COVID-19, of these opportunities through the adverse event management taper, which could encourage physicians to take on the treatment of these patients because it gives them the tool to know how to make that experience successful, the arrival of the guidelines and the promise of that webinar that indicated that we were going to be included. Those are drivers that will contribute in addition to the raised awareness of respiratory health. And the importance of that, particularly in this kind of a population that increased index of suspicion, plus all of the baseline patients who are not seeing physicians now but are postponing, and we expect to come back.

All of those come together. I don't think we can quantify it, but it is possible certainly to qualitatively describe all of those coming together as we return to the new normal. I don't know, Roger, if you'd add anything to that.

Roger Adsett -- Chief Operating Officer

Yeah. No, I would agree with that. I mean, certainly, we didn't quantify it in our survey work. We didn't ask the physicians to quantify that.

But certainly, the -- what we're seeing is a deferral right now. It's not an elimination of the prescription. I think the -- when the patients come back into the offices and reengage with the physicians, you're going to see that prescribing accelerate. I would also say that the index of suspicion and the increased attention on respiratory disease is a positive outcome of this.

I think the physicians are looking at their patients and recognizing how vulnerable they are. And as much as they can treat the patients and get them into -- their lungs into as healthy a state as possible, I think the better everybody is going to be, and certainly, for those patients. And so that's what they're reporting is that index of suspicion, their urgency to call the patient back into their offices as soon as they can, is what I think is very encouraging as we think about the signs going forward.

Liisa Bayko -- JMP Securities -- Analyst

Are patients able to initiate therapy kind of -- or are they doing this vis-à-vis telemedicine? Is that happening?

Will Lewis -- Chairman and Chief Executive Officer

Is that happening? Yes. Roger, do you want to give any detail?

Roger Adsett -- Chief Operating Officer

Yeah. So, there's -- so we're certainly seeing new patient starts. We are -- we have reports from physicians that they are able to make the decision to put patients on ARIKAYCE, if they were not responding adequately to the background therapy. So, they're a refractory patient.

As I mentioned, the payers are relaxing some of their criteria for reauthorizations and sputum testing. So, physicians are able to, through an attestation process, get the reimbursement. And then we're able to support those patients virtually through our ARIKAYCE field trainers, get them onboarded through different means. We can either do a video chat with them and walk them through the device and what to expect from therapy.

Or we talk with them over the phone with supplemental video support from the website as to -- with instructions. So, we are able and continue to support the onboarding of new patients throughout all of this.

Liisa Bayko -- JMP Securities -- Analyst

OK, great. And then just -- I wanted to ask a little bit more about brensocatib and its potential role in ARDS. Well, can you maybe talk about sort of the delayed onset of action and yet how you still think there may be an opportunity and a window for it to work in ARDS given that, that also has a relatively short window? I'm just curious how you think about that.

Will Lewis -- Chairman and Chief Executive Officer

Yes. No, I appreciate the question because it allows me to say, once again, the proper pronunciation of this new word which is brensocatib when I introduced today.

Liisa Bayko -- JMP Securities -- Analyst

OK.

Will Lewis -- Chairman and Chief Executive Officer

No, no. That's OK. I got it wrong when I started out, and I can't tell you how many times I practiced it. But I'm going to actually ask Martina to address the thought process behind this question, which is, you know, it takes a couple of weeks for a full pharmacodynamic effect, yet in the context of COVID-19 severe patients why we think this might be particularly useful.

I think the one thing I would just say at the outset is the principal investigator from our Phase II WILLOW study, Professor Chalmers, is in fact the one who is directing this study. So, his thorough understanding of the mechanism of action, I think, is what -- and his experience with the drug is what informed his enthusiasm to approach us to want to initiate this study. But maybe, Martina, you can talk about the science a bit.

Martina Flammer -- Chief Medical Officer

Yeah. Sure. So Liisa, in COVID-19, we basically have a acute inflammatory process in the lung. And at the early stages, this is neutrophil-driven.

Then neutrophil proteases, by blocking the neutrophil elastase and proteases, we hope that we will impact to stop that lung damage and potentially also the progression to ARDS. In the early stages, ARDS is characterized by heavy neutrophil influx into the lung. And because there is a high density of neutrophils, there may be even an opportunity for brensocatib to work faster. And yes, you're right.

In WILLOW, we've seen that the earliest we even were statistically significant by day 15. While the maximum effect, which you see by week -- by the fourth week of treatment in ARDS can develop in various stages. And what you've seen in this disease with COVID-19 is, some patients, they get the infection, they show fever, they show all the symptoms, then they do – they're kind of OK between and then they start progressing, and they come back. And you see bilateral infiltrates in the lung, and all the inflammatory mark is up.

So, it is interesting to see how different ARDS present in different type of infection. So, we believe that there is an opportunity for brensocatib to start working and then help patients not to progress and actually come out with a better outcome, so they don't have to necessarily go on to mechanical ventilation.

Liisa Bayko -- JMP Securities -- Analyst

Thank you.

Operator

The next question comes from Graig Suvannavejh from Goldman Sachs. Please go ahead.

Graig Suvannavejh -- Goldman Sachs -- Analyst

Congrats on a quarter -- really nice quarter. Just maybe one question, just for modeling purposes. Obviously, the first quarter the numbers were below budget, I think, is what you mentioned. And then as we're anticipating in the second half, you know, a number of new clinical trial starts.

Can you maybe perhaps give us a sense of, at least relative to what you're originally budgeting, how we should be thinking about the flow of quarterly OpEx throughout the balance of the year. So that's, I guess, for you, Sarah. And then maybe two questions on the pipeline. One, just wanted to get your latest thoughts on the abscessus trial.

I noticed it wasn't mentioned in the press release. And then secondly, just on the Phase III program in non-CF BE, any sense of what the size of the program might look like? I know you had a fairly large Phase II. And so, any thoughts on kind of how many patients you might need, you know, for an approval there? And how long the trials might be?

Will Lewis -- Chairman and Chief Executive Officer

Sure. I'll start with the last question first. I -- we don't have that number sort of locked down yet. I think we want to talk more fully about the entirety of the Phase III program with FDA in more detail before we sort of lock into final trial design.

If you look at historical precedents, certainly hundreds of patients. I think the prior trials may be a good proxy for what may be needed, although our effect was more dramatic than what they had seen, so that may mitigate that a little bit. The abscessus trial is certainly still on the agenda. That is not one we are trying to get started necessarily by the end of the year, but we'll see how that evolves.

I think our primary objectives strategically are clearly to get the frontline study in MAC, the Phase III study in 1007, and the Phase I program in 1009, while we're expanding geographically and securing approval in Europe and Japan. So that's a pretty full agenda. And I think we certainly are interested in getting approval to treat abscessus, especially given the strength of the investigator-initiated study and the data that showed such impressive results with our drug that was released at last year's American Thoracic Society. But we want to make sure we do everything in a high-quality way, and so it may be that abscessus needs to follow behind the initiation of those other two trials that are the strategic focus at the moment.

OpEx, I'll turn it over to Sarah to talk about how we're thinking about that for the balance of the year.

Sara Bonstein -- Chief Financial Officer

Thanks, Graig. I appreciate the question. So, as we mentioned in our prepared remarks, there are obviously a lot of uncertainties with COVID-19, and you know, we had previously pulled revenue and operating expense at the same level of sort of uncertainties. And what we felt was a more important metric for yourself and the investment community as you think about modeling is really on our financial resources.

And so that's why we had communicated that we feel confident that we have financial resources that could carry us into 2022. In this current year, we do have the pivotal programs that we have on the docket to start later this year. We will obviously see some increase in OpEx once those start, but we feel confident we have financial resources to carry us in 2022.

Graig Suvannavejh -- Goldman Sachs -- Analyst

Thank you very much. Congrats again on the quarter.

Will Lewis -- Chairman and Chief Executive Officer

Yeah, thanks.

Operator

The next question comes from Josh Schimmer from Evercore ISI. Please go ahead.

Joshua Schimmer -- Evercore ISI -- Analyst

Thanks for taking the questions. I'm not sure if I missed that, if you had given the number of new patient adds over the quarter. I think that's something you've given in the past. Not sure if you're comfortable giving it to us for the first quarter.

And also, given your -- the target age demographic for ARIKAYCE and their potential susceptibility to SARS-CoV-2, both in terms of, you know, the idea that they may be at higher-risk given age, but they may also be at lower-risk given some of the active inflammatory process in the lungs that could confer some protections against the virus. So, have you seen any -- among your patients, any impact directly from COVID-19 or not?

Will Lewis -- Chairman and Chief Executive Officer

Yeah. I'll just turn that over to Roger to talk about new patient starts and anything we've seen in terms of detail at the patient level, experiencing the COVID-19 pandemic.

Roger Adsett -- Chief Operating Officer

Yeah, thanks, Will. So we're not sharing new patient starts at this point, and we're trying to give more qualitative direction as to we think the new patients. Certainly, there's been a delay as patients are putting off or postponing their visits, but the second half is when we really anticipate that we'll see that -- some return normalcy and physicians calling patients in to examine and to make sure that they're prescribing appropriately. So, there's increased focus on NTM patients.

And I think that while we --obviously not privy to patients talking about or sharing their medical conditions, I think that the increased attention from the physicians as to what they report on their NTM patients, and they've very much pivoted toward making sure that patients who are on ARIKAYCE, and they've already made that prescriber decision to stay on ARIKAYCE. So, they're very concerned about maintaining their health and making sure that they continue to take their medication. I think the urgency to call the patients in the raised index of suspicion that the physicians are reporting also reflects the concern that this patient population may be vulnerable. And I think, you know, if we contrast that to many of the conversations we had when we launched ARIKAYCE back in the fourth quarter of 2018, physicians didn't call their patients in to initiate.

They waited until their regular appointments for the patients to show up and prescribe ARIKAYCE. So, this is a change in behavior. And I think it is a reaction to the concern and focus on respiratory health and particularly around NTM. And I think that there's a much greater sense of urgency as what they're reporting to us for these -- to take care of these patients.

So, I would say that reflects more of the, you know, -- they think these patients are potentially vulnerable rather than protected.

Joshua Schimmer -- Evercore ISI -- Analyst

I understand where [Inaudible]

Will Lewis -- Chairman and Chief Executive Officer

Although, I think it's in the previous proposition, Josh. And I think we -- scientifically, we've not looked at that, but I think it probably warrants some additional attention. And so, I would just -- we'll put a pin in that one and maybe get back to you. I think, generally, on the new patient starts, on the metrics and stuff.

Philosophically, I just have to say, last year, we spent -- prior to COVID-19, a lot of time, putting on a lot of detail with the intention of being transparent and trying to communicate in a way that would be helpful to people who are modeling and understanding what was going on with the launch. I think we did that as effectively as we could. I'm not sure that the additional detail actually helped, notwithstanding our incredibly strong performance. So philosophically, I'm sort of in a place where I feel like the best thing for us to do is to just deliver the performance and have that stand as the information that's of greatest relevance.

Joshua Schimmer -- Evercore ISI -- Analyst

Got it. Thanks so much.

Will Lewis -- Chairman and Chief Executive Officer

You bet, Josh.

Operator

This concludes our question-and-answer session. I would like to turn the conference back over to Will Lewis for any closing remarks.

Will Lewis -- Chairman and Chief Executive Officer

Just thank you to everyone for dialing in and bearing with us through the long Q&A. I certainly appreciate the interest in the company. And we hope you all remain safe and healthy through this unusual time. Thanks, everyone.

Operator

[Operator signoff]

Duration: 72 minutes

Call participants:

Sara Bonstein -- Chief Financial Officer

Will Lewis -- Chairman and Chief Executive Officer

Martina Flammer -- Chief Medical Officer

Roger Adsett -- Chief Operating Officer

Matthew Harrison -- Morgan Stanley -- Analyst

Adam Walsh -- Stifel Financial Corp. -- Analyst

Martin Auster -- Credit Suisse -- Analyst

Ritu Baral -- Cowen and Company -- Analyst

Joe Schwartz -- SVB Leerink -- Analyst

Liisa Bayko -- JMP Securities -- Analyst

Graig Suvannavejh -- Goldman Sachs -- Analyst

Joshua Schimmer -- Evercore ISI -- Analyst

More INSM analysis

All earnings call transcripts